Pramipexole protects against MPTP toxicity in non-human primates

Journal of Neurochemistry

Volumn 96, Issue 5, 2006, Pages 1315-1321

  Iravani, Mahmoud M ^a   Haddon, Claire O ^a   Cooper, J Mark ^b   Jenner, Peter ^a   Schapira, Anthony H ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Dopamine; Dopamine agonist; Mitochondria; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BENZOTHIAZOLES; CALLITHRIX; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MPTP POISONING; THIAZOLES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; CALLITHRIX JACCHUS; PRIMATES;

EID: 33645101158     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03625.x     Document Type: Article

References (26)

1. Abramova NA. Cassarino DS. Khan SM. Painter TW. Bennett JP. Jr. 2002 Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma JNeurosciRes 67 494 500
2. Ahlskog JE. 2003 Slowing Parkinson's disease progression: recent dopamine agonist trials Neurology 60 381 389
3. Cassarino DS. Fall CP. Smith TS. Bennett JP. Jr. 1998 Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion JNeurochem 71 295 301
4. Dawson TM. Dawson VL. 2003 Molecular pathways of neurodegeneration in Parkinson's disease Science 302 819 822
5. Di Monte DA. 2003 The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2 531 538
6. Finotti N. Castagna L. Moretti A. Marzatico F. 2000 Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment PharmacolRes 42 287 291
7. Gassen M. Gross A. Youdim MB. 1998 Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine MovDisord 13 242 248
8. Gu M. Iravani MM. Cooper JM. King D. Jenner P. Schapira AH. 2004 Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms JNeurochem 91 1075 1081
9. Hughes AJ. Daniel SE. Ben Shlomo Y. Lees AJ. 2002 The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service Brain 125 861 870
10. 2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist Brain Res 838 51 59
11. Iravani MM. Syed E. Jackson MJ. Johnston LC. Smith LA. Jenner P. 2005 A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets EurJNeurosci 21 841 854
12. 3 receptor BMC Biolq22 2 22
13. Kitamura Y. Kohno Y. Nakazawa M. Nomura Y. 1997 Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice JpnJPharmacol 74 51 57
14. Kitamura Y. Kosaka T. Kakimura JI. Matsuoka Y. Kohno Y. Nomura Y. Taniguchi T. 1998 Protective effects of the anti-parkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells MolPharmacol 54 1046 1054
15. Movement Disorders Society. 2002 Management of Parkinson's disease: an evidence-based review MovDisord 17 S1 S166
16. 2 receptor prevents apoptosis in dopaminergic cell lines BiochemJ 373 25 32
17. Ogawa N. Tanaka K. Asanuma M. Kawai M. Masumizu T. Kohno M. Mori A. 1994 Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro Brain Res 657 207 213
18. Parkinson's Study Group 2002 Dopamine transporter brain imaging to assess the effects of promipexole vs levodopa on Parkinson's disease progression JAMA 287 1653 1661
19. Schapira AH. Olanow CW. 2004 Neuroprotection in Parkinson disease JAmMedAssoc 291 358 364
20. Sethy VH. Wu H. Oostveen JA. Hall ED. 1997 Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats Brain Res 754 181 186
21. Stephan B. Baron G. Schwerdtfeger W. 1980 The Brain of Common Marmosets: a Stereotaxis Atlas, pp. q23 XX XX Springer-Verlag Berlin
22. Vu TQ. Ling ZD. Ma SY. Robie HC. Tong CW. Chen EY. Lipton JW. Carvey PM. 2000 Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine JNeural Transm 107 159 176
23. Whone AL. Watts RL. Stoessl AJ. et al. 2003 Slower progression of Parkinson's disease with ropinirole versus levodopa. The REAL-PET Study AnnNeurol 54 93 101
24. Youdim MB. Arraf Z. 2004 Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax Neuropharmacology 46 1130 1140
25. Zou L. Jankovic J. Rowe DB. Xie W. Appel SH. Le W. 1999 Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity Life Sci 64 1275 1285
26. Zou L. Xu J. Jankovic J. He Y. Appel SH. Le W. 2000 Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice NeurosciLett 281 167 170